Migraines are a debilitating condition characterized by painful, throbbing headaches that are often accompanied by nausea and/or sensitivity to light and sound. During a migraine attack, more than 90 percent of patients are unable to work or function normally, severely disrupting their life. The condition affect tens of millions of Americans each year, and approximately five million people in the United States fall into the more severe subpopulation of migraine sufferers that experience five or more attacks per month.
Despite the high prevalence of migraines, few effective treatment options exist for chronic migraine sufferers. Current therapeutics on the market, such as triptans or dihydroergotamines (DHEs), are not effective for all patients or carry unwanted side effects and risks. The dominant therapeutic strategy is to use methods that cause blood vessel constriction. More recent research has now identified an alternate mechanism for stopping blood vessel dilation through targeting neuropeptides, such as calcitonin gene-related peptide (CGRP), that are involved at the origin of migraine pain.
ALD403, a potent monoclonal antibody to CGRP, targeted for the treatment of migraines, is currently being evaluated in a proof-of-concept clinical study in frequent episodic migraineurs. For more information, please visit this study's page at clinicaltrials.gov or send an email to the clinical team at Alder Biopharmaceuticals.